Skip to content

#Analysis and opinion

19 OctMon
  1. The Microdose (UC Berkeley BCSP)41

    Maastricht psychopharmacologists Mason and Haijen-Bongers call for research on menstrual cycle effects in psychedelic trials

    Psychopharmacologists Natasha Mason and Eline Haijen-Bongers argue that clinical trials of psychedelics for depression and PTSD rarely account for female sex hormones, in a review in Nature Molecular Psychiatry. They cite a preprint pooling their psychedelic trial data in which women given the same dose responded more strongly and reported greater anxious ego dissolution. The review notes 5-HT2A receptor density rises when estrogen is high.

15 OctThu
19 SepSat
  1. Europe PMC: new psychedelic research papers52

    Review examines psychedelics and suicidality as a double-edged sword

    A review examines the relationship between classic psychedelics such as LSD, psilocybin and DMT and suicidality, proposing a theoretical double-edged sword model. The authors report that several deaths followed non-medical psychedelic use in unsafe contexts, with unclear suicidal intent, and that rare cases of increased suicidal ideation and behaviours in clinical settings showed no significant differences from placebo groups or established causality.

11 AugTue
  1. MAPS62

    MAPS responds to report that Resilient has resubmitted its MDMA therapy NDA to FDA

    MAPS said it welcomed a new FDA evaluation after an August 9 report by Psychedelic Alpha that Resilient Pharmaceuticals (formerly MAPS PBC and Lykos Therapeutics) had resubmitted its new drug application for MDMA-assisted therapy for PTSD. The resubmission follows the Complete Response Letter issued on August 9, 2024, which recommended additional research on durability of response, safety characterisation and steps to minimise potential bias, and MAPS noted it comes without a new Phase 3 study. MAPS, which funded the clinical research completed in 2022 and says it has no active role in Resilient's drug development, also pointed to the FDA's final July 2026 guidance, Psychedelic Drugs: Considerations for Clinical Investigations, as reflecting approaches it developed with the agency.

22 MayFri
20 MayWed
18 MayMon